1、1 0 De c e m be r 2 02 4Q325Financial ResultsO ct o be r 30,2 02 5Forward-Looking StatementsStatements included in this document that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Gilead cautions readers that fo

2、rward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially.These risks and uncertainties include those relating to:Gileads ability to achieve its full year 2025 financial guidance,including as a result of the uncertainty of the amount

3、 and timing of Veklury revenues,the impact of the Inflation Reduction Act,changes in U.S.regulatory or legislative policies,and changes in U.S.trade policies,including tariffs;Gileads ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy;Gileads

4、ability to accelerate or sustain revenues for its virology,oncology and other programs;Gileads ability to realize the potential benefits of acquisitions,collaborations or licensing arrangements;the risk that Gileads U.S.manufacturing and R&D investments may not achieve their intended benefits;patent

5、 protection and estimated loss of exclusivity for our products and product candidates;Gileads ability to initiate,progress or complete clinical trials within currently anticipated timeframes or at all,the possibility of unfavorable results from ongoing and additional clinical trials,and the risk tha

6、t safety and efficacy data from clinical trials may not warrant further development of Gileads product candidates or the product candidates of Gileads strategic partners;Gileads ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that